Abbott Laboratories (ABT) is down roughly 3% in Tuesday trading as the market continues to reprice the company after last week’s guidance cut, which Abbott tied to the near-term earnings dilution and integration costs from its recently completed Exact Sciences acquisition. The move also reflects lingering skepticism around near-term segment momentum, particularly Nutrition, following the latest quarter’s update and outlook reset. (finance.yahoo.com)

On April 16, Abbott reduced its 2026 adjusted EPS outlook, explicitly flagging the impact of the Exact Sciences transaction. That guidance reset re-anchored expectations for 2026 profitability and has remained the main overhang on the stock in subsequent sessions, with investors weighing the trade-off between near-term dilution and the longer-term strategic logic of building an oncology diagnostics platform. (finance.yahoo.com)

Beyond the initial guidance cut, sell-side models have been getting refreshed and price targets adjusted lower in the wake of the outlook change, which can create incremental selling as investors reassess valuation and near-term earnings power. At the same time, Abbott’s positive oncology narrative has been highlighted by new Cancerguard data presented around AACR 2026, but that longer-dated opportunity is not yet enough to offset the near-term hit to earnings in today’s tape. (defenseworld.net)

Key swing factors over the next several weeks include evidence that Nutrition trends are stabilizing, integration execution on Exact Sciences (including synergy timing and costs), and any updates that further clarify the earnings bridge from near-term dilution to longer-term growth. Investors will also monitor litigation-related headlines after a recent $70 million jury verdict tied to Similac Special Care, which adds another risk layer that can amplify volatility around an already guidance-sensitive stock. (morningstar.com)